원문정보
초록
영어
Galactosemia is a potentially lethal disorder caused by the deficiency of the enzyme galactose-1-phosphate uridyltransferase (GALT) within the Leloir pathway. Galactokinase (GALK) is the enzyme in Leloir pathway which converts α-D galactose to galactose 1-phosphate. The elevated level of galactose-1 -phosphate, the product of GALK plays a major role in Galactosemia. Therefore the inhibition of GALK is a novel therapy for this disorder. Hence in the present study, we performed molecular docking of twenty inhibitors with different activity against galactokinase into the active site of galactokinase enzyme. The binding mode of these inhibitors was obtained using Surflex dock program interfaced in Sybyl-X2.0. The residues such as SER141, TYR109, ARG105, ARG228, TYR106, GLY346, GLY136, ASP86, ASP186 and SER142 found to interact with inhibitors.
목차
1. Introduction
2. Materials and Methods
2.1. Ligand Preparation
2.2. Protein Preparation
2.3. Molecular Docking
3. Results and Discussion
3.1. Validation of Surflex Dock
3.2. Molecular Docking
4. Conclusion
References